Safety of Dexmedetomidine in Severe Traumatic Brain Injury
Status:
Withdrawn
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess the safety and feasibility of dexmedetomidine as an
adjunct to conventional sedative therapy compared to conventional sedative therapy alone in
patients with severe traumatic brain injury.
Phase:
Phase 2
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore
Collaborators:
Hospira, Inc. Hospira, now a wholly owned subsidiary of Pfizer